Innate Pharma (IPHA) Receivables (2017 - 2025)
Innate Pharma's (IPHA) quarterly Receivables came in at $15.4 million in Q4 2025, up 184.46% YoY from $5.4 million in Q4 2024, and down 21.67% on a QoQ basis from $19.6 million in Q2 2025.
Innate Pharma (IPHA) Receivables (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Receivables data on file, last reported at $15.4 million in Q4 2025.
- Quarterly Receivables rose 184.46% year-over-year to $15.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.4 million (up 184.46% YoY) and the FY2025 annual result came in at $15.4 million, changed 0.05% from the prior year.
- Receivables eased to $15.4 million in Q4 2025, from $19.6 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $71.7 million in Q2 2022 to a low of $5.4 million in Q4 2024.
- A 5-year average of $44.9 million and a median of $54.8 million in 2021 frame the typical range for Receivables.
- Annual changes were most pronounced in 2021 — Receivables plunged 99.65% — and 2025, when it soared 184.46%.
- Tracing IPHA's Receivables over 5 years: stood at $56.1 million in 2021, then declined by 4.54% to $53.6 million in 2022, then soared by 32.99% to $71.2 million in 2023, then plunged by 92.41% to $5.4 million in 2024, then soared by 184.46% to $15.4 million in 2025.
- The last three Receivables figures came in at $15.4 million (Q4 2025), $19.6 million (Q2 2025), and $5.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | 14.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.38 Mn |
| Jun 30, 2025 | 19.64 Mn |
| Dec 31, 2024 | 5.41 Mn |
| Jun 30, 2024 | 37.33 Mn |
| Dec 31, 2023 | 71.24 Mn |
| Jun 30, 2023 | 62.41 Mn |
| Dec 31, 2022 | 53.57 Mn |
| Jun 30, 2022 | 71.73 Mn |
| Dec 31, 2021 | 56.12 Mn |
| Jun 30, 2021 | 56.52 Mn |
| Dec 31, 2020 | 26.89 Mn |
| Jun 30, 2020 | 15.95 Bn |
| Dec 31, 2019 | 21.35 Mn |
| Dec 31, 2018 | 297.56 Mn |
| Dec 31, 2017 | 25.37 Mn |